Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.55 |
| ▸ | ACACB | O00763 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | CASR | P41180 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20063913 | 0.87 | NOTUM (0.57) | NOTUMACACBPOLBLMNAHTT | |
| SCHEMBL21838700 | 0.87 | NOTUM (0.57) | NOTUMACACBPOLBLMNAHTT | |
| SCHEMBL20063903 | 0.86 | NOTUM (0.51) | NOTUMACACBPOLBLMNAHTT | |
| SCHEMBL20063899 | 0.86 | NOTUM (0.51) | NOTUMACACBPOLBLMNAHTT | |
| SCHEMBL22499987 | 0.85 | NOTUM (0.57) | NOTUMACACBPOLBLMNAHTT | |
| SCHEMBL29689683 | 0.85 | NOTUM (0.57) | NOTUMACACBPOLBLMNAHTT | |
| SCHEMBL20063898 | 0.85 | NOTUM (0.49) | NOTUMACACBPOLBLMNAHTT | |
| SCHEMBL25080907 | 0.81 | NOTUM (0.54) | NOTUMACACBPOLBMAPTGAA | |
| SCHEMBL1337157 | 0.80 | CACNA1B (0.63) | NOTUMACACBPOLBLMNAHTT | |
| SCHEMBL3711639 | 0.78 | CKS1B (0.51) | NOTUMACACBPOLBLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | NOTUM 3035/4885ACACB 4731/4885POLB 4679/4885 |
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | NPY5R, REN, F12 | NOTUM 3035/4885ACACB 4731/4885POLB 4679/4885 |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | NOTUM 3022/4885ACACB 4749/4885POLB 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.